Recurrence patterns and site-level survival in the previous phase III study of IL13-PE38QQR: Implications for drug distribution variability.

2017 Background: Interleukin-13–Pseudomonas Exotoxin A (IL13-PE38QQR) is a targeted cytotoxic fusion protein directed against the IL13α2 receptor expressed on glioblastoma stem cells and absent in normal brain tissue. The drug is administered by convection-enhanced delivery (CED) for recurrent glioblastoma (GBM). Early-phase studies demonstrated durable tumor control and long-term survival; however, a pivotal Phase III trial failed to meet its primary endpoint. We hypothesized that variability in clinical outcomes was driven primarily by limitations in drug delivery rather than tumor biology. Methods: We conducted a post hoc analysis of clinical, imaging, and survival data from the randomized Phase III PRECISE trial of IL13-PE38QQR versus Gliadel wafers. Treatment-site experience was defined as ≥3 efficacy-evaluable IL13-PE38QQR patients. A subset of patients underwent radiolabeled drug infusion to assess intraparenchymal distribution. Recurrence patterns were evaluated using serial MRI. Survival outcomes were compared by treatment arm and site experience. Results: Marked heterogeneity in drug distribution was observed in patients receiving radiolabeled IL13-PE38QQR, ranging from broad target coverage to minimal or absent delivery. In the IL13-PE38QQR arm, treatment at experienced centers correlated with significantly improved overall survival (median OS 48.4 vs 32.1 weeks; p=0.038), whereas site experience had no significant impact in the control arm. A 50% increase in 1-year survivorship was observed in the treatment arm compared with control. Long-term survivors most commonly exhibited distant or multifocal recurrence with relative preservation of the treated region, suggesting durable local tumor control where therapeutic exposure was achieved. Conclusions: Clinical outcomes following IL13-PE38QQR therapy were strongly associated with delivery efficiency and treatment-team experience. Radiolabeled distribution studies, experience-dependent survival effects, and recurrence patterns in long-term survivors indicate that outcome variability was driven primarily by technical limitations in drug delivery rather than tumor biology. This study represented the first large-scale evaluation of CED in the absence of purpose-built delivery technology, relying on complex, nonstandardized surgical workflows. These findings highlight the importance of standardized procedures, specialized training, and purpose-built delivery platforms to enable reproducible therapeutic exposure and optimize the clinical potential of IL13-PE38QQR. Clinical trial information: NCT00076986 .